Welcome to our dedicated page for Corcept Therapeutics news (Ticker: CORT), a resource for investors and traders seeking the latest updates and insights on Corcept Therapeutics stock.
Corcept Therapeutics Inc. (NASDAQ: CORT) generates frequent news as a commercial-stage pharmaceutical company focused on cortisol modulation in endocrinology, oncology, metabolic disease and neurology. Company updates often highlight progress with Korlym, which Corcept describes as the first FDA-approved medication for patients with endogenous hypercortisolism, and with a pipeline of selective glucocorticoid receptor antagonists and other cortisol modulators.
News about Corcept commonly covers clinical trial milestones in hypercortisolism, solid tumors, ALS and liver disease. Examples include data from the CATALYST program in patients with difficult-to-control type 2 diabetes and hypercortisolism, the pivotal ROSELLA Phase 3 trial of relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer, the BELLA Phase 2 trial in gynecologic cancers, the MONARCH Phase 2b trial in MASH, and the DAZALS trial of dazucorilant in ALS. Company communications also describe upcoming or ongoing studies of nenocorilant in combination with immunotherapy in solid tumors.
Investors following CORT news will see regular regulatory and corporate announcements, such as New Drug Application (NDA) submissions and FDA acceptance for review of relacorilant in hypercortisolism and platinum-resistant ovarian cancer, a Marketing Authorization Application (MAA) to the European Medicines Agency, and an FDA Complete Response Letter requesting additional evidence of effectiveness for relacorilant in hypertension secondary to hypercortisolism. Quarterly earnings releases and corporate updates, reported via press releases and Form 8-K filings, provide information on product revenue from Korlym, operating expenses and the company’s cash and investment position.
This CORT news page on Stock Titan aggregates these public disclosures so readers can monitor Corcept’s clinical data presentations, regulatory milestones, financial results and other material events in one place. Users interested in endocrine disorders, ovarian cancer, MASH, ALS or cortisol biology can review the evolving news flow to understand how Corcept’s programs are progressing over time.
Corcept Therapeutics (NASDAQ: CORT) announced positive results from its Phase 3 GRACE trial of relacorilant for treating hypercortisolism (Cushing’s syndrome). The trial met its primary endpoint, showing significant improvements in hypertension, hyperglycemia, and other symptoms. In the randomized withdrawal phase, patients receiving relacorilant had a notably lower loss of blood pressure control compared to those on placebo (odds ratio: 0.17; p-value: 0.02). The drug was well-tolerated, with no significant safety differences observed. Corcept plans to submit a New Drug Application in Q3, with additional data presentations scheduled for June.
Corcept Therapeutics Incorporated reported strong financial results for the first quarter of 2024, with a revenue of $146.8 million, a 39% increase from the same period in 2023. The company raised its 2024 revenue guidance to $620 - $650 million and reported a net income per common share of $0.25. Corcept continues to focus on developing medications for various disorders by modulating the effects of cortisol. The company highlighted record numbers of new prescribers and patients for its drug Korlym in the first quarter, showcasing its growing presence in the market.
Corcept Therapeutics Incorporated has completed enrollment in the Phase 4 CATALYST trial, the largest study ever conducted to establish the prevalence of hypercortisolism in patients with difficult-to-control type 2 diabetes. Approximately 25% of the over 1,000 patients enrolled were identified as having hypercortisolism, a higher rate than previously assumed. Final prevalence data will be shared at the American Diabetes Association’s 84th Scientific Sessions in June, with treatment data expected by year-end. The findings from CATALYST aim to improve the identification and treatment of patients with hypercortisolism.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.